Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 and/or Tremelimumab with SBRT in Pancreatic Cancer
NCT02868632Phase 1Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Aug 2016
- Primary completion
- Mar 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by NYU Langone Health. Primary endpoint: Overall Survival at 24 months. Planned start Aug 2016; status: withdrawn.
02
Drugs
durvalumabtremelimumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02868632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02868632.